FIGURE
Figure 1.
- ID
- ZDB-FIG-250214-23
- Publication
- Wawruszak et al., 2025 - Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies
- Other Figures
- All Figure Page
- Back to All Figure Page
Figure 1.
Histone acetylation modifications in cancer biology. (a) The chemical structure of selisistat (EX527) – sirtuin 1 (SIRT1) inhibitor. (b) Cellular localisation of SIRT1. (c) Inhibition of histone deacetylation (DEACETYLATION OFF) (catalyzed by SIRT1 (HDAC)) through EX527. After inhibition, HDACs are unable to remove acetyl groups (Ac) from the N-terminus lysine residues. This leads to an opened state of the chromatin and increases transcriptional activity of RNA polymerase II (RNAPII). |
Expression Data
Expression Detail
Antibody Labeling
Phenotype Data
Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ J Enzyme Inhib Med Chem